Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
51,727,908
-
Number of holders
-
21
-
Total 13F shares, excl. options
-
3,127,151
-
Shares change
-
-212,515
-
Total reported value, excl. options
-
$9,694,108
-
Value change
-
-$923,501
-
Number of buys
-
7
-
Number of sells
-
-8
-
Price
-
$3.1
Significant Holders of SAB Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share (SABS) as of Q2 2024
25 filings reported holding SABS - SAB Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share as of Q2 2024.
SAB Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share (SABS) has 21 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 3,127,151 shares
of 51,727,908 outstanding shares and own 6.05% of the company stock.
Largest 10 shareholders include BVF INC/IL (917,826 shares), RTW INVESTMENTS, LP (766,946 shares), MARSHALL WACE, LLP (459,168 shares), Sessa Capital IM, L.P. (458,457 shares), VANGUARD GROUP INC (276,336 shares), GEODE CAPITAL MANAGEMENT, LLC (59,415 shares), MILLENNIUM MANAGEMENT LLC (52,784 shares), Pathstone Holdings, LLC (50,650 shares), FIRST MANHATTAN CO. LLC. (24,577 shares), and First PREMIER Bank (19,386 shares).
This table shows the top 21 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.